Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.69 - $1.21 $16,160 - $28,339
-23,421 Reduced 71.48%
9,344 $9,000
Q1 2022

May 12, 2022

BUY
$1.02 - $3.8 $7,131 - $26,569
6,992 Added 27.13%
32,765 $39,000
Q4 2021

Feb 14, 2022

BUY
$3.26 - $4.66 $44,336 - $63,376
13,600 Added 111.72%
25,773 $84,000
Q3 2021

Nov 15, 2021

SELL
$4.08 - $5.66 $52,521 - $72,861
-12,873 Reduced 51.4%
12,173 $54,000
Q2 2021

Aug 16, 2021

SELL
$5.01 - $7.48 $47,364 - $70,715
-9,454 Reduced 27.4%
25,046 $136,000
Q1 2021

May 17, 2021

BUY
$7.19 - $14.95 $150,040 - $311,976
20,868 Added 153.08%
34,500 $258,000
Q4 2020

Feb 16, 2021

SELL
$6.66 - $14.66 $45,474 - $100,098
-6,828 Reduced 33.37%
13,632 $148,000
Q3 2020

Nov 16, 2020

BUY
$8.69 - $14.47 $105,444 - $175,578
12,134 Added 145.74%
20,460 $181,000
Q2 2020

Aug 13, 2020

BUY
$5.21 - $11.03 $43,378 - $91,835
8,326 New
8,326 $89,000
Q4 2019

Feb 07, 2020

SELL
$4.52 - $10.1 $12,149 - $27,148
-2,688 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$7.14 - $11.65 $17,200 - $28,064
2,409 Added 863.44%
2,688 $28,000
Q2 2019

Aug 13, 2019

BUY
$5.5 - $9.75 $1,534 - $2,720
279 New
279 $3,000
Q1 2019

May 14, 2019

SELL
$5.51 - $9.59 $50,328 - $87,595
-9,134 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$5.55 - $11.34 $45,021 - $91,990
8,112 Added 793.74%
9,134 $50,000
Q3 2018

Nov 13, 2018

SELL
$9.74 - $12.92 $7,967 - $10,568
-818 Reduced 44.46%
1,022 $12,000
Q2 2018

Aug 15, 2018

BUY
$10.16 - $13.65 $18,694 - $25,116
1,840 New
1,840 $19,000
Q1 2018

May 15, 2018

SELL
$9.47 - $12.98 $207,108 - $283,872
-21,870 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$8.45 - $17.48 $116,728 - $241,468
13,814 Added 171.47%
21,870 $213,000
Q3 2017

Nov 14, 2017

BUY
$13.52 - $23.75 $108,917 - $191,330
8,056
8,056 $118,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.